# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-24-054172
Filing Date
2024-04-29
Accepted
2024-04-29 17:12:28
Documents
5

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | tm243000d2_defa14a.htm | DEFA14A | 19691
2 | GRAPHIC | tm243000d2_defa14aimg01.jpg | GRAPHIC | 447363
3 | GRAPHIC | tm243000d2_defa14aimg02.jpg | GRAPHIC | 321786
4 | GRAPHIC | tm243000d2_defa14aimg03.jpg | GRAPHIC | 429540
5 | GRAPHIC | tm243000d2_defa14aimg04.jpg | GRAPHIC | 296326
| Complete submission text file | 0001104659-24-054172.txt |  | 1989404

Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39202 | Film No.: 24892680
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)